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ABSTRACT
Objectives: The credibility of models rests on their
validity. An age-structured decision analytic model, Eco-
nomic Varicella VaccInation Tool for Analysis (EVITA),
has been developed to examine the epidemiologic and
economic effects of universal varicella (chicken pox) vac-
cination in Germany. EVITA combines a varicella trans-
mission module describing the spread of infection in a
population over time with a second module describing
the course of disease in case of an infection. Any vacci-
nation strategy can be assessed dependent on coverage
levels and targeted age group. Model input data include
epidemiologic, clinical, and economic information,
which were mainly derived from actual varicella cases
(retrospective survey). The objective of this study was to
illustrate the efforts undertaken to validate the EVITA
model.
Methods: We assess the descriptive validity, i.e., whether
the model provides an adequate picture of the reality and
covers all relevant aspects of the spread of varicella and
the course of disease. Analyzing the consistency of the
model results with observable data does technical veriﬁ-
cation. Face validity, i.e., the consistency with the under-
lying theoretical basis of the spread of varicella, is
analyzed with respect to results on possible age shifts and
elimination of varicella. Tests of corroboration, or con-
vergent validity, are performed by comparisons with other
models.
Results: Without vaccination, the EVITA model predicts
undiscounted, indirect costs of €154 million, nearly
40,000 complications and 5,700 hospitalizations per year
owing to varicella. These results, especially the distribu-
tion of complications and hospitalizations, ﬁt well with
population-based survey data. The development of the
EVITA model is based on an established epidemiologic
model and on real-life data from the survey, ensuring
descriptive validity. Results on age shifts and elimination
show face validity. Although other models differ consid-
erably with respect to methods applied, the economic
results of EVITA, i.e., a beneﬁt–cost ratio of 4.12 when
vaccinating young children, lies in the range found in
other studies. This underscores its convergent validity.
Comparable with other studies, discount rates and price
of vaccine proved to be most sensitive variables.
Conclusions: EVITA provides a powerful tool to simulate
the highly complex processes associated with varicella
infections and the impact of vaccination. The results of
EVITA provide a reliable tool for informed decision mak-
ing and should enhance the acceptance of such models.
Keywords: economic evaluation, methodology, modeling,
validity, varicella vaccination.
Introduction
Models are increasingly used in the ﬁeld of health
economics. They are developed to assist decision
makers in evaluating options and making choices
[1]. Modeling allows one to extrapolate beyond the
follow-up period of clinical trials to assess longer
lasting effects, and it is used to predict costs and
consequences of alternative courses of action, e.g.,
therapeutic choices, based on epidemiologic base-
line data [2]. The value of models is not restricted to
the results they produce, but they also help to reveal
the logical connection between assumptions, inputs,
and outputs [3]. Modeling is often unavoidable
in economic evaluations as health economists
are interested in the cost-effectiveness of applying
health technologies under almost real-life condi-
tions rather than solely in efﬁcacy in a controlled
clinical trial setting. Modeling is, thus, used to
extrapolate beyond data observed in a trial, to link
intermediate clinical end points to ﬁnal outcomes or
to generalize results to other settings [4]. A good
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example for the necessity of modeling is the evalu-
ation of immunization programs where efﬁcacy
data such as seroconversion rates provide only lim-
ited evidence on the power of vaccination in pre-
venting infectious diseases in a population or
community [5]. This is especially true for highly
contagious infectious diseases like measles or vari-
cella where vaccination programs can generate indi-
rect, herd immunity effects on the population.
Whereas models are established in a variety of
domains, which also involve decisions about health
and life such as environmental protection, their use
in health care decision making is still controversial
[6]. Although the majority of problems with health
economic analyses relates to uncertainty in the esti-
mates of comparative clinical efﬁcacy data that are
due to unavailability of randomized trials, poor-
quality trials, or ﬂawed analyses and interpretation
of trials, and not to economic modeling issues [7],
there is concern about the credibility of models per
se [1]. A decision maker’s consideration of model
analysis, therefore, rests on the understanding of the
model’s workings and its logical connections. This
understanding, in turn, depends on the transpar-
ency in the presentation of a model and its results as
well as its overall quality. Quality assessment com-
prises three criteria: structure, data, and validation
[3]. It has been suggested that sections on validation
and quality control should be included in any
reporting format for modeling studies [8]. A model’s
structure and data inputs can generally be assessed
in peer-reviewed publications. Validation efforts
generally form a considerable part of modeling
and are carried out often, e.g., for submissions
to authorities for approval, pricing, or formulary
access. Nevertheless, most publications of modeling
studies can and do devote only limited space and
attention to illustrating these efforts [9].
The objective of this article is to present valida-
tion efforts for a health economic model on vari-
cella (chicken pox) vaccination. This model named
EVITA (Economic Varicella VaccInation Tool for
Analysis) has been developed to analyze the clinical,
epidemiologic, and health economic effects of vari-
cella vaccination strategies in Germany, including
the strategy of no universal vaccination. The no-
vaccination arm provides insight in the population-
based burden of varicella, whereas the model’s
results on the cost-effectiveness of vaccination strat-
egies can aid decisions on resource allocation.
EVITA consists of two modules. The ﬁrst module is
an infectious disease model, which describes the epi-
demiologic aspects of varicella infection in a popu-
lation over time. The second module depicts the
clinical course of the disease and its economic impli-
cations. Both modules, individually and jointly, will
be evaluated.
The next section describes the evaluation criteria
used to assess the validity of the EVITA model. The
following section provides a brief description of the
model, which has been published elsewhere [10].
The validity of the model is then assessed accord-
ing to the evaluation criteria, and conclusions are
drawn.
Evaluation Criteria for Validity Assessment
Several sets of criteria for assessment of a model’s
validity have been developed [1,3,6,9,11–13] and
applied [9]. Although the terminology differs
between these sets, and different methodologies
have been used to test the criteria, the sets cover
mostly the same aspects, but are weighted differ-
ently. The criteria used to assess the validity of the
EVITA model cover the range of criteria that can be
found in the literature.
The ﬁrst criterion is descriptive validity [12].
Models shall provide a simpliﬁed, but adequate pic-
ture of reality. A model shall consider all relevant
aspects and omit only those aspects that do not alter
its results and conclusions signiﬁcantly. The second
criterion is the veriﬁcation, or the technical validity,
of the model [6,9]. Veriﬁcation includes processes to
ensure the model’s proper functioning. This can be
achieved, for example, by means of debugging.
Calibration is an additional step in the veriﬁcation
of a model. Here, the consistency of the model with
observable data is tested. The third criterion is face
validity [3,6,9]. Face validity is given when a model
produces outputs that are consistent with the theo-
retical basis of the disease and the medical interven-
tion or can be explained intuitively on this basis.
These three criteria can be interpreted as tests of the
internal validity of a model. The fourth criterion is
corroboration or convergent validity. Corrobora-
tion is a test of between-model validation and deals
with uncertainties in the modeling process. Differ-
ent independent models addressing the same ques-
tion should give the same or similar results and,
more importantly, lead to the same conclusions.
If results or conclusions differ, those differences
should be explainable [3,6,9].
The strongest criterion for the validity of a model
is the so-called predictive validity, which relates the
modeling results to real-life outcomes [3,6,9]. Tests
of predictive validity are only possible if the mod-
eled situation is observable, measurable, constant in
its structure over time, and constant across varia-
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tions of conditions not speciﬁed in the model. In
reality, such a situation is not usually given. Tests of
predictive validity are judged to be valuable, but not
absolutely essential [3,6]. Sendi et al. [9] performed
a test of predictive validity by cross-validation, i.e.,
by basing their model analysis on a subset of their
data and by comparing the outputs of the model
with the remainder of the data set. With regard to
the EVITA model, such an approach was not feasi-
ble, as no data are available on the effects of
universal varicella vaccination in Germany. The pre-
dictive validity of the EVITA model could, there-
fore, not be assessed.
Description of the EVITA Model
The decision analytic model EVITA has been devel-
oped to compare the potential clinical, epidemio-
logic, and economic effects of varicella vaccination
strategies to no general vaccination. Figure 1 illus-
trates the model. The model combines two modules.
The ﬁrst module is based on a dynamic infectious
disease model that was developed by Halloran et al.
[14,15]. This module is an age-structured, deter-
ministic model where the population is divided into
groups of susceptible, infectious, and immune indi-
viduals. Transition between these groups is calcu-
lated with a set of partial differential equations that
model the spread of varicella infection over time in
the population. The spread of infection depends on
the age-speciﬁc infection rates, i.e., the age-speciﬁc
force of infection, combined with the number of
susceptible, infectious, and immune individuals in
each of the subgroups. Herd immunity effects are
considered in this dynamic model as the spread of
infection slows as more people become immune.
Immunity can be induced either by a previous con-
tact with the pathogen or by successful immuniza-
tion with a vaccine. In contrast to this approach, a
static model would not cover herd immunity effects
because the spread of infection solely depends on
infection rates and the number of susceptible
individuals.
To adapt the dynamic model to Germany, input
data for the spread of infection were collected in a
German seroprevalence study, conducted for this
purpose, which will be described brieﬂy later in this
article [16]. The age structure of the population is
drawn from ofﬁcial statistics. Within this module,
the effect of different, deﬁned vaccination strategies
on the spread of varicella can be modeled for the
German population. Differing vaccination coverage
rates and age targets for the vaccinees can deﬁne
vaccination strategies. A strategy of no universal
vaccination has also been assessed. Vaccine efﬁcacy
was assumed to be 86% based on clinical trial data.
Immunity was assumed to wane at a rate of 0.5%
per year.
The second module of the EVITA model
describes the course of varicella and its potential
complications as well as the associated health-care
resource utilization (see Fig. 1). Input data on the
medical management, epidemiology of varicella
complications, hospitalization rates, number of
inpatient days, and work days lost were taken from
a German epidemiologic survey that was speciﬁcally
designed to collect the data for the development of
this module [17,18]. This survey is also described
brieﬂy later in this article.
Outputs from the EVITA model are the age-
speciﬁc incidence of varicella and related complica-
tions over time associated with a chosen vaccination
strategy and the costs of varicella as well as beneﬁt–
cost ratios (BCR). The BCR is deﬁned as the quo-
tient of the savings induced by the vaccination strat-
egy and the costs of carrying out the vaccination
strategy. BCRs above one express net savings and
are an indicator for the return of investment of the
vaccination strategy. BCRs are widely used in eco-
nomic evaluations of vaccines. The BCR allows
better comparisons across different vaccination pro-
grams and different countries than the measure of
net beneﬁts of those programs that depend on the
number of vaccinees, for instance. The EVITA
model has been extensively described elsewhere
[10].
Input data of the model were taken mainly
from two large epidemiologic surveys [16–18] and
were complemented by data from ofﬁcial statis-
tics and the literature. The ﬁrst, a seroprevalence
survey [16], is based on a cross-sectional, age-
stratiﬁed, representative sample of the GermanFigure 1 Simpliﬁed model framework.
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population aged between 0 and 79 years. The
sample size was calculated on the basis of previ-
ous studies to reach 95% conﬁdence intervals
(CIs) with an accuracy of 6% for prevalence rates
below 80%, 4% for prevalence rates above 80
and 2% when the prevalence rate is above 95%.
Based on this calculation, 4602 sera from two
serum banks that have been collected between
1995 and 1999 by the Robert Koch-Institute,
Berlin, Germany, were analyzed with an indirect
enzyme immunoassay (EIA), Enzygnost anti-VZV/
IgG (Dade Behring, Marburg, Germany). Samples
with EIA levels below 500 IU/L were tested addi-
tionally with an in-house ﬂuorescent antibody to
membrane antigen assay, which served as the gold
standard in case of discrepant results.
For the second, epidemiologic survey [17,18], a
sample size of 1190 cases was calculated on the
basis of the results of a pilot study to obtain an
accuracy of 1% for the 95% CI of the overall com-
plication rate. A countrywide, representative sam-
ple of 1334 unvaccinated varicella cases from 1999
was acquired from randomly selected pediatricians,
GPs, and internists. Data have been collected
retrospectively from medical ﬁles via structured tel-
ephone interviews. These data include sociodemo-
graphic data such as age at diagnosis, sex, number
of siblings, epidemiologic data on the severity of
diseases, complications, hospitalizations, and med-
ical resource utilization data like physician contacts,
medication, duration of hospitalization and work
days lost. The latter can be divided into workdays
lost by patients or by parents who are absent from
work to care for their sick child. In Germany, sick-
ness funds compensate parents’ loss of earnings by
paying so-called “childcare beneﬁts” in line with the
Social Security Act. Comparable legal requirements
do not exist in other countries. Apart from the epi-
demiologic data, the indirect costs of varicella were
compiled in this survey and were calculated to have
amounted to €150 million for the German popula-
tion in 1999 [17].
Validation of the EVITA Model
This section reports the efforts undertaken to vali-
date the EVITA model and the results of the valida-
tion process. We start with the internal validation
covering the aspects of descriptive validity, technical
veriﬁcation, and face validity. We then detail the
results of the external validation, i.e., the compari-
son of the EVITA model with other models analyz-
ing varicella vaccination.
Descriptive Validity
The varicella transmission module is based on an
established and peer-reviewed model. Thus, it is
consistent with accepted theory on the spread of
varicella infection in a population and adequately
describes the spread of infection over time. The
adaptation to German conditions was performed
using German data that was speciﬁcally collected
for the modeling purposes as described above [16].
The second module of the model was developed on
the basis of the large, representative survey that pro-
vided real-life data from Germany on the course of
the disease and related resource utilization [17,18].
The data and the development of this module were
reviewed by a German expert panel and deemed to
provide an adequate picture of the course of vari-
cella and its clinical management in Germany.
Given the acceptance of the data sources and the
model structure, the EVITA model fulﬁlls the con-
ditions of descriptive validity.
Veriﬁcation
Veriﬁcation relates to the consistency of the model
results with known inputs and outputs and the
model’s proper technical functioning, in particular
the absence of coding or calculation errors. The
technical functioning was tested by means of an
extensive sensitivity analysis. Extreme values of the
input variables were used, and the model’s actual
outputs were compared with expected outcomes.
Two examples of these sensitivity analyses illustrate
these efforts: For instance, as would have been
expected, extreme values like varicella death rates
of zero yielded no varicella-related death. Similarly,
when assuming zero vaccine efﬁcacy or zero cover-
age rates the model calculated the same outcomes in
the “vaccination” and in the “no-vaccination” arms
in line with expectations. As the model calculates
both the vaccination and the no-vaccination arms
separately, this latter sensitivity analysis is compa-
rable to a double implementation strategy. In such a
strategy, a model is independently implemented
twice and the results of both versions are checked
for their consistency. This analysis was performed in
the validation process described by Sendi et al. [9].
Calibration of the model was carried out by cal-
culating the force of infection, i.e., the age-speciﬁc
annual attack rate of varicella, using the data from
the seroprevalence study [16] and by comparing
the result with the number of cases observed in
Germany. The number of varicella cases ﬂuctuates
from year to year. The model calculates an average
of 739,000 varicella cases per year, with the average
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being dependent on the length of the observation
period. This ﬁgure underestimates the mean number
of 756,000 cases per year, ﬂuctuating between
737,000 and 778,000 cases, which were observed
in Germany during the years 1998 to 2001 [19].
Nevertheless, owing to the natural ﬂuctuations of
varicella incidence, the model was assessed to satis-
factorily ﬁt reality, as its imputed average number of
cases lies within the range of actual observations in
Germany and is, if anything, a conservative esti-
mate. The model predicts an average of 39,700
complications per year, 5,700 of which require hos-
pitalization. The distribution of these complications
and hospitalizations ﬁts very well with the distribu-
tion derived from the epidemiologic survey [17] (see
Fig. 2).
According to the epidemiologic survey, about 1
million days of work were lost for both varicella-
infected individuals and caregivers in 1999 in
Germany, resulting in overall costs of €150 million
[17]. The model calculates an average indirect cost
of €154 million per year, which also corresponds
well to known facts. Overall, the model can, there-
fore, be successfully veriﬁed.
Face Validity
The consistency of the results with the underlying
theory can be illustrated by examining the question
whether varicella can be eliminated by any of the
vaccination strategies. In general, elimination is
achieved when the prevalence falls to below a pre-
determined, very low level [20]. The so-called “crit-
ical coverage levels” needed to eliminate varicella
are usually cited in the literature to lie between 86
and 91% [21]. Those ﬁgures rest on two important
issues. The ﬁrst one is the assumption that the
so-called reproduction number is constant and
not inﬂuenced by the immunization program. The
reproduction number is the number of new infec-
tions occurring for each single infection in a
completely susceptible population. It is deﬁned as
the product of the number of contacts of an infec-
tious individual per day, the probability of trans-
mission of a pathogen, and the duration of
infectiousness measured in days. The higher the
reproduction number, the higher the critical cover-
age rate for the elimination of an infectious disease
[21]. The aim of an immunization program is to
lower the reproduction number to below one. Pop-
ulations are never fully susceptible, either because
of immunity caused by the previous contact with
the pathogen or by vaccination, if a vaccination
program is in place. Furthermore, vaccinated people
are less likely to transmit a pathogen, as the dura-
tion of their infectiousness may be lowered. There-
fore, the real reproduction number in a population
Figure 2 Distribution of complications and hospitalization taken from the epidemiologic survey [17,18] and as calculated by the EVITA model.
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differs from the one assumed when determining the
critical coverage rate [15]. Second, the age at infec-
tion plays a crucial role. The critical coverage rates
for varicella elimination of 86% to 91% do not take
into account the age structure of infections and the
age at vaccination. If vaccinees are immunized ear-
lier than at the median age of infection, the coverage
rate necessary to achieve elimination will be low-
ered [15]. Based on this theoretical consideration,
an early vaccination of children may result in a
lower required coverage needed to eliminate vari-
cella than the ﬁgures cited in the literature. The
EVITA model predicts that by vaccinating children
aged 15 months a coverage rate of at least 75%
would be required to eliminate varicella within 30
years. Figure 3 shows the relationship between the
target age of vaccinees and the associated coverage
rate necessary to achieve elimination as derived by
the model. In Germany, the median age of infection
with varicella-zoster virus (VZV) is 5 years [17,18].
Figure 3 shows that, according to the EVITA model,
if the target vaccination age is 5 years, coverage
rates of about 90% are necessary to eliminate vari-
cella. This result corresponds well to the range of
86% to 91% that is cited in the literature [21].
When vaccinating much earlier in childhood, elim-
ination can be achieved with much lower coverage
rates, highlighting that a young age of vaccinees is
the most important factor in achieving elimination.
EVITA model results are, therefore, in line with the-
oretical considerations.
Face validity of the EVITA model can also be
illustrated with respect to the possibility of a shift of
varicella to older age groups reﬂected in a higher
incidence in adolescents or adults. As varicella
infections are more likely to be severe and associ-
ated with complications in adolescents and adults,
an age shift would be a negative external effect of a
vaccination program. The reason for this possible
phenomenon can be explained as follows: If only a
part of each birth cohort is immunized, the spread
of infection will slow, because less individuals are
susceptible within a population. As the pathogen
remains in the population, susceptible individuals
are still likely to become infected, but, given the
slowdown in the spread of infection, the infection
occurs at a later age. Such an age shift was observed
in the Greek population with regard to rubella,
because vaccination coverage was lower than 50%
for a relatively long period of time [22]. The EVITA
model shows that within the ﬁrst years after the
start of an immunization program covering young
children, the number of cases decreases in every
age group independently of the coverage rate. Of
course, the greatest decrease occurs in the group of
preschool children if the age at immunization is 15
months. The ﬁnding can be explained by the effects
of herd immunity, i.e., the reduced rate of infection
in an unvaccinated population owing to the immu-
nization of a part of the population. The pattern of
these results is supported by evidence from sur-
veillance of varicella after the introduction of the
vaccination program in the United States in the mid-
1990s [23]. The age distribution of varicella cases
has already changed in the United States and the
mean age of infection increased because the reduc-
tion in the incidence was more pronounced in chil-
dren than in adolescents and adults. Nevertheless,
this is no age shift in the sense of an increase in the
absolute number of cases in any of the older age
groups.
When looking further into the future, the picture
can be expected to change, as depicted by the
EVITA analysis. After 30 years, an increase of the
total number of cases over this whole period can be
observed in adolescents and adults at coverage rates
below 50%. The greatest increase can be expected
in the group of 21- to 30-year-old persons (see Fig.
4). These dynamics of varicella can be explained as
follows: Today, most adolescents and adults have
already contracted varicella and are immune. When
vaccinating only a portion of children, these
immune adolescents and adults will not be at a
higher risk of infection. Therefore, no age shift can
be expected in the short run. Nevertheless, in the
long run, the group of unvaccinated children devel-
ops partly into a group of susceptible adolescents
and adults. Thus, only in the long run an age shift
can occur, and the model calculates that it will occur
only at coverage rates lower than 50%.
Figure 3 Age of vaccines and minimum required coverage rate to
eliminate varicella in Germany within the analytic time horizon of 30
years.
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The examples of model-derived coverage rates
required for varicella elimination as well as the
analysis of the threat of an age shift demonstrate
that the EVITA model results correspond well to
theoretical considerations. Face validity of the vari-
cella transmission model can therefore be judged as
good. Overall, based on the criteria of descriptive
validity, veriﬁcation, and face validity, the model
fulﬁlls the criteria of internal validity.
Corroboration (Convergent Validity)
Corroboration tests were performed by comparing
results of other models with the result of the EVITA
model. Because most models are static models and,
thus, do not cover effects of herd immunity, elimi-
nation of varicella was not reported. This is also
true for the dynamic model by Coudeville et al. [24]
in which the spread of infection after vaccination is
described over a comparable period of time. In this
model a different vaccination strategy was analyzed
in contrast to the EVITA model. Coudeville et al.
vaccinate only a part of the birth cohort in the
second life-year while the remaining children are
vaccinated during the preschool age (third to sixth
life-year). Because early vaccination is crucial for
elimination of varicella, one cannot expect elimina-
tion in the model by Coudeville et al. under this
immunization program. Following effect of the
immunization was reported by Coudeville et al.:
The prevalence of varicella falls after starting the
immunization program, followed by a slight raise to
an endemic equilibrium, which is much lower than
the equilibrium before starting the immunization
program. When analyzing a similar immunization
strategy with the EVITA model like the one ana-
lyzed by Coudeville et al., the resulting prevalence
over time coincides with the one reported by
Coudeville et al. (see Fig. 5). This provides evidence
for corroboration.
Several health economic models have assessed
the costs and beneﬁts of routine varicella vaccina-
tion [24–31]. In the following, the corroboration of
the EVITA model is assessed by a comparison with
these models. The models differ with respect to the
methods that have been applied and with respect to
the vaccination strategies. Most studies applied
static modeling, i.e., the force of infection is
assumed to be constant such that no effects of herd
immunity occur. It was argued that dynamic models
covering herd immunity effects are more suitable
for evaluations of vaccination programs [5]. Only
the models in the studies by Coudeville et al. [24],
Brisson et al. [30], and Lieu et al. [31] used dynamic
modeling like the EVITA model. In most studies, the
analytic time horizon for the vaccination program
was 30 years, in line with EVITA. Exceptions are
the studies by Diez-Domingo et al. [27], Scuffham
et al. [28], and Beutels et al. [26] with 20, 25, and
70 years, respectively. Future costs were discounted
at a rate of 5% in all but the study of Brisson et al.
[30] in which a discount rate of 3% was used. Table
1 provides an overview on the vaccination strate-
gies, the assumption on the vaccine efﬁcacy, and the
BCRs. From a societal perspective, BCRs range
from 1.61 to 5.40, reﬂecting net-savings. The result
of the EVITA model ﬁts well in this range. Dif-
ferences in the magnitude of the results can be
explained by differences in the assumptions made as
well as the epidemiologic situations and the organ-
Figure 5 Projected number of varicella cases in Germany following
the introduction of a immunization program: 65% of the children of
each birth cohort are vaccinated at the age of 15 months, and 75% of
the remaining unvaccinated and still susceptible children of these
cohorts are vaccinated at the age of 4 years.
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ization of the health-care systems in the countries
studied.
When examining BCRs from a payer’s perspec-
tive, differences in health-care systems produce even
more differentiated results, with the EVITA model
generating the highest BCR. This is caused by the
fact that in Germany, indirect costs are partly cov-
ered by the sickness funds, i.e., parents’ absence
from work to care for a sick child is paid for by the
sickness funds and not by the employer. In the other
countries that were analyzed in the studies, no such
regulation exists resulting in lower costs to payers.
Even the study by Beutels et al. [26] that also eval-
uates varicella vaccination in Germany did not take
these childcare beneﬁts into account.
When focusing only on directs costs to payers
without the “childcare beneﬁts,” the BCR would be
0.74 and is, thus, in the range reported in the other
studies. The difference in results from the payers’
perspective can therefore be explained by the spe-
ciﬁc legal situation in Germany.
Generally, there is a high consistency between the
EVITA model [10] and the results of the sensitivity
analyses reported in the other studies with regard to
the inﬂuential variables, i.e., discount rates, costs of
vaccine and costs of work loss, as well as less sen-
sitive variables, i.e., efﬁcacy and waning of immu-
nity. Overall, these considerations illustrate that
the model demonstrates a good convergent validity
with the other models that have been used to eval-
uate varicella vaccination programs.
Conclusions
Health economic models are intended to assist
health-care decision-making. The acceptance of
models is highly dependent on their validity. The
process of validation is not usually described exten-
sively in scientiﬁc publications of models. In this
article, we reported on the validation process under-
taken in the case of the EVITA model that has been
developed to analyze the effects of varicella vacci-
nation programs in Germany with the aim of
assisting decision making on future vaccination
strategies. Based on the criteria of descriptive valid-
ity, face validity, veriﬁcation, and corroboration,
also known as convergent validity, we provided
evidence that the EVITA model can be judged to be
a valid model. The EVITA model provides a pow-
erful tool to simulate the highly complex process
associated with varicella infections and the impact
of vaccination strategies. The results of the EVITA
model provide a sound basis for scenario analysis
and informed decision making and should further
increase the acceptance of such models by health
care decision makers.
This study was supported by a grant from
GlaxoSmithKline.
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